Research Output per year
Fingerprint Dive into the research topics where Emmanuel Antonarakis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 16 Similar Profiles
Prostatic Neoplasms
Medicine & Life Sciences
Castration
Medicine & Life Sciences
docetaxel
Medicine & Life Sciences
Androgen Receptors
Medicine & Life Sciences
Androgens
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Prostate-Specific Antigen
Medicine & Life Sciences
Disease-Free Survival
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2002 2019
Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer
Taplin, M. E., Antonarakis, E. S., Ferrante, K. J., Horgan, K., Blumenstein, B., Saad, F., Luo, J. & de Bono, J. S., Dec 2019, In : European Urology. 76, 6, p. 843-851 9 p.Research output: Contribution to journal › Article
Castration
Androgen Receptors
Prostatic Neoplasms
Circulating Neoplastic Cells
MDV 3100
A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
Antonarakis, E., Jan 1 2019, (Accepted/In press) In : Oncologist.Research output: Contribution to journal › Article
Prostatic Neoplasms
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
Kapoor, R., Deek, M. P., McIntyre, R., Raman, N., Kummerlowe, M., Chen, I., Gaver, M., Wang, H., Denmeade, S., Lotan, T., Paller, C., Markowski, M., Carducci, M., Eisenberger, M., Beer, T. M., Song, D. Y., Deweese, T. L., Hearn, J. W., Greco, S., Deville, C. & 7 others, , Jun 13 2019, In : BMC cancer. 19, 1, 572.Research output: Contribution to journal › Article
Open Access
Salvage Therapy
Prostatectomy
Double-Blind Method
Prostatic Neoplasms
Radiotherapy
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer
McHugh, D., Eisenberger, M., Heath, E. I., Bruce, J., Danila, D. C., Rathkopf, D. E., Feldman, J., Slovin, S. F., Anand, B., Chu, R., Lackey, J., Reyno, L., Antonarakis, E. & Morris, M. J., Jan 1 2019, In : Investigational New Drugs.Research output: Contribution to journal › Article
Castration
Prostatic Neoplasms
Maximum Tolerated Dose
Antibodies
Fatigue
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer
Paller, C., Piana, D., Eshleman, J., Riel, S., Denmeade, S. R., Isaacsson Velho, P., Rowe, S., Pomper, M. G., Antonarakis, E., Luo, J. & Eisenberger, M., Jan 1 2019, In : Prostate. 79, 14, p. 1597-1603 7 p.Research output: Contribution to journal › Article
Prostatic Neoplasms
Circulating Neoplastic Cells
Therapeutics
Castration
Prostate-Specific Antigen